IN DEPTH

Anemia and Iron Deficiency in Heart Failure
Current Concepts and Emerging Therapies

ABSTRACT: Anemia and iron deficiency are important and common comorbidities that often coexist in patients with heart failure. Both conditions, together or independently, are associated with poor clinical status and worse outcomes. Whether anemia and iron deficiency are just markers of heart failure severity or whether they mediate heart failure progression and outcomes and therefore should be treated is not entirely clear. Treatment of anemia in patients with heart failure with erythropoiesis-stimulating agents has been evaluated intensively during the past several years. Unfortunately, these agents did not improve outcomes but were associated with a higher risk of adverse events. Iron deficiency in patients with heart failure can be absolute, when total body iron is decreased, or functional, when total body iron is normal or increased but is inadequate to meet the needs of target tissues because of sequestration in the storage pool. Whereas iron replacement is appropriate in patients with anemia resulting from absolute iron deficiency, it has been unclear whether and how absolute or functional iron deficiency should be treated in nonanemic patients with heart failure. Recently, small studies found that administration of intravenous iron in patients with heart failure and absolute or functional iron deficiency with or without anemia improves symptoms and exercise capacity, but long-term outcomes and safety data are not yet available. In this review, we discuss the causes and pathogenesis of and treatment options for anemia and iron deficiency in patients with heart failure.

Key Words: anemia • erythropoietin • heart failure • iron • renal insufficiency, chronic

© 2018 American Heart Association, Inc.
Remarkable advances in our understanding of the pathogenesis of heart failure (HF) have led to rational therapies with considerable improvement in patient outcomes. Despite this, however, the prognosis of HF remains poor. Anemia and iron deficiency (ID) are 2 important comorbidities common in patients with HF and are associated with poor clinical status and worse outcomes. If anemia and ID are indeed mediators of poor outcomes in patients with HF, correcting these comorbidities would be attractive and novel therapeutic targets to improve outcomes. Although several small studies showed that use of erythropoiesis-stimulating agents (ESAs) to increase hemoglobin in patients with HF with reduced ejection fraction (HFrEF) is associated with beneficial effects on clinical outcomes, the neutral results of the large pivotal RED-HF trial (Reduction of Events With Darbepoetin Alfa in Heart Failure) suggest that anemia by itself is probably not a mediator of poor outcomes but rather a marker of HF severity. Although data from recent trials suggest that treating ID itself may be of benefit, significant knowledge gaps exist in our understanding of why, how, and for how long anemia or ID should be treated in HF and the mechanisms underlying the observed effects of treatment. In this review, we describe the magnitude of the problem of anemia and ID in patients with HF, discuss their impact on long-term outcomes, and examine whether and how they should be managed in light of recent clinical trial data.

**PREVALENCE OF ANEMIA IN HF**

The prevalence of anemia in patients with HF (defined as hemoglobin <13 g/dL in men and <12 g/dL in women) is approximately 30% in stable and 50% in hospitalized patients, regardless of whether patients have HFrEF or HF with preserved ejection fraction, compared with <10% in the general population (although prevalence increases with age, exceeding 20% in subjects ≥85 years old). Compared with nonanemic patients with HF, anemic patients are older and more likely to be female and to have diabetes, chronic kidney disease (CKD), severe HF with worse functional status, lower exercise capacity, worse health-related quality of life (Qol), greater edema, lower blood pressure, greater requirement of diuretics, and higher neurohormonal and proinflammatory cytokine activation. However, anemic subjects have a better left ventricular (LV) ejection fraction (LVEF): Hemoglobin is inversely related to LVEF, and an increase in hemoglobin over time is associated with a decrease, not an increase, in LVEF.

**CAUSES OF ANEMIA IN HF**

In the general elderly population, anemia is caused by nutritional deficiencies (primarily iron), chronic inflammatory/CKD, or unexplained anemia of the elderly (a hypoproliferative anemia with blunted erythropoietin response) in approximately one third each, with primary hematologic diseases or other conditions accounting for smaller proportions. Identification of absolute ID mandates a search for its cause, particularly gastrointestinal blood loss from benign or malignant conditions.

The pathogenesis of anemia in HF (reviewed previously) is multifactorial (Figure 1). ID is common in HF and is discussed separately. However, deficiencies of hematonic vitamins (B12 or folate) are infrequent. Erythropoietin, which stimulates the production of red blood cells (RBCs), is produced primarily within the renal cortex and outer medulla by specialized peritubular fibroblasts and is often abnormal in HF. Low PO2 is the primary stimulus for erythropoietin production. Renal dysfunction is common in HF, but structural renal disease, which could reduce erythropoietin production, is infrequent. However, an imbalance between oxygen supply and demand related to increased proximal tubular sodium reabsorption caused by low renal blood flow and glomerular filtration rate reduces renal PO2, activates hypoxia-inducible factor-1α and induces erythropoietin gene transcription. Therefore, erythropoietin levels are increased in proportion to HF severity but are lower than expected for the degree of anemia, suggesting blunted erythropoietin production. However, the relationship between renal blood flow and erythropoietin secretion during HF is complex and not fully understood.

Inflammation is an important component of HF. Tumor necrosis factor-α, interleukin-6 and several other proinflammatory cytokines, also C-reactive protein are increased in HF and inversely related to hemoglobin level. Interleukin-6 and tumor necrosis factor-α also inhibit renal erythropoietin production by activating transcription factors GATA binding protein 2 (which binds nucleotide consensus sequence GATA in target gene promoters) and nuclear factor κ light-chain enhancer of activated B cells and may explain the blunted erythropoietin response. These cytokines also inhibit bone marrow erythroid progenitor cell proliferation. However, in some patients with HF, erythropoietin levels are excessively elevated, and high erythropoietin levels are associated with worse outcomes.

The renin-angiotensin system plays an important role in erythropoietin pathophysiology through multiple pathways. First, angiotensin II decreases PO2 by reducing renal blood flow and increasing oxygen demand and thereby stimulates erythropoietin production. Angiotensin II also directly stimulates bone marrow erythroid progenitor cell production. Therefore, angiotensin-converting inhibitors and angiotensin receptor blockers cause a modest reduction in hemoglobin by...
decreasing production of erythropoietin and erythroid progenitors and by preventing breakdown of the hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline. Finally, anemia might be related to hemodilution, although clinically euvoicmic patients have normal plasma volume and measurement of hemoglobin reflects “true anemia” as assessed by RBC volume in the vast majority of anemic patients with HF.

Opasich and colleagues identified a specific cause of anemia in only 43% of 148 patients with stable HF. ID was seen in only 5% of patients. In the remaining 57% of patients, proinflammatory cytokine activation, inadequate erythropoietin production, or defective iron utilization was found despite adequate iron stores, indicative of anemia of chronic disease (functional ID). Therefore, an activated proinflammatory state and anemia of chronic disease could be the most frequent underlying cause of anemia in HF. Recent reports show that mutation (eg, clonal hematopoiesis of indeterminate potential) or deficiency of genes that regulate hematopoiesis results in an increase in inflammatory cytokines, including interleukin-1β and -6, and is associated with an increased incidence of coronary heart disease in humans and with worsening of cardiac remodeling in mice. Future studies may further elucidate such mechanistic interactions between the hematopoietic and cardiovascular systems.

**PATHOPHYSIOLOGICAL CONSEQUENCES OF ANEMIA**

In patients with very severe anemia (hemoglobin, 4–6 g/dL) and normal LV function, usually seen with helminthic infections in developing countries, reduced oxygen-carrying capacity evokes nonhemodynamic and hemodynamic compensatory mechanisms (reviewed previously). There is an increase in RBC 2,3-diphosphoglycerate that displaces the hemoglobin-oxygen dissociation curve to the right, increasing tissue oxygen...
delivery. A low number of circulating RBCs reduces systemic vascular resistance\textsuperscript{28} by decreasing whole-blood viscosity, and low hemoglobin enhances nitric oxide–mediated vasodilation,\textsuperscript{29,30} The resulting decrease in arterial blood pressure causes baroreceptor-mediated neurohormonal activation,\textsuperscript{28} identical to that seen in low-output HF.\textsuperscript{17,18} Increased sympathetic and renin-angiotensin activity decreases renal blood flow and glomerular filtration rate, resulting in renal retention of salt and water with the expansion of extracellular and plasma volumes. Therefore, severe anemia itself may cause the syndrome of high-output HF in subjects with normal LV function, and correction of severe anemia in these patients causes a rapid and complete regression of high-output HF.\textsuperscript{18} Although these hemodynamic and neurohormonal responses are observed in severe anemia, it is unclear whether and to what extent these mechanisms are also operative in patients with HFrEF with less severe anemia. Detailed hemodynamic and echocardiographic studies have not been reported in patients with HFrEF before and after treating anemia. However, when hemoglobin was increased from 8.5 to 10 to 14 g/dL by erythropoietin in patients with CKD and moderate anemia, cardiac output (7.0 to 6.6 to 5.2 L/min) and LV fractional shortening (36% to 33% to 29%) decreased progressively, proportional to the increase in hemoglobin.\textsuperscript{15} Therefore, all this evidence implies that increasing hemoglobin in patients with HFrEF would increase systemic vascular resistance, raise the LV afterload, and cause the LVEF to decrease. This sequence of events could explain the observed inverse relationship of hemoglobin with LVEF\textsuperscript{8,9,12} and the findings that an increase in hemoglobin over time is associated with a decrease in LVEF.\textsuperscript{9,13} These findings might also explain why correction of anemia in patients with HFrEF has not improved outcomes.

**ASSOCIATION OF ANEMIA WITH OUTCOMES**

Anemia is independently associated with increased mortality and hospitalizations in patients with both HFrEF and HF with preserved ejection fraction.\textsuperscript{3,7,8,31} The association of hemoglobin level with mortality is not linear, and most of the increased risk occurs at low hemoglobin.\textsuperscript{3,32,33} Some studies have reported a J-shaped relationship between hemoglobin and mortality in the normal population\textsuperscript{34} and patients with coronary artery disease,\textsuperscript{35} acute coronary syndromes,\textsuperscript{36} and HF.\textsuperscript{21,33} The lowest mortality risk was observed in the hemoglobin range of 13 to 16 g/dL, and the risk increased with hemoglobin concentrations below or above this range. Thus, the concern is that excessive increases in hemoglobin may be associated with increased mortality. In a meta-analysis of 33 studies involving >150,000 patients with HF, anemia doubled the relative risk of death.\textsuperscript{37} A similar relationship was observed in patients with new-onset anemia and in patients with a decrease in hemoglobin over time.\textsuperscript{11} Moreover, a spontaneous increase in hemoglobin and the resolution of anemia over time were associated with a better prognosis, similar to that of patients without anemia.\textsuperscript{38} Anemia and CKD often coexist in patients with HF. Whereas anemia doubles the risk of death in patients with HF, the adjusted risk of death is further increased 1.5-fold in the presence of CKD.\textsuperscript{39} These findings, however, do not clarify whether anemia is a mediator or just a marker of HF severity.

**MECHANISMS ASSOCIATED WITH POOR OUTCOMES IN HF WITH ANEMIA**

Multiple mechanisms appear to contribute to poor outcomes in these patients. Reduced oxygen delivery to metabolizing tissues in anemic subjects triggers a host of hemodynamic, neurohormonal, and renal alterations,\textsuperscript{28} leading to increased myocardial workload, which could cause adverse LV remodeling and LV hypertrophy.\textsuperscript{10,41} Moreover, patients with HF and anemia have several comorbidities, including CKD, cardiac cachexia-associated poor nutritional status, and low albumin,\textsuperscript{8,11,39} all of which could worsen outcomes. Finally, the neurohormonal and proinflammatory cytokine activation seen in patients with HF may have diverse deleterious consequences.\textsuperscript{13,21,28}

**TREATMENT OPTIONS**

**Should Anemia in Patients With HF Be Treated?**

Most of the aforementioned observational studies suggest that anemia is common in patients with HF and is associated with poor clinical status and worse prognosis. It is therefore reasonable to consider whether treatment of anemia might improve outcomes. Unfortunately, few options are available to increase hemoglobin.

Whereas packed RBC transfusion can be used as a short-term therapy, transfusions are associated with many risks and provide only temporary benefit. Kao and colleagues\textsuperscript{2} examined the large public discharge database on 596,456 patients admitted for HF. Anemia was present in 27% of patients with HF. Whereas untreated anemia was associated with \( \approx 10\% \) increased adjusted risk of mortality, the adjusted risk of mortality was \( \approx 70\% \) higher in anemic patients with HF who received transfusions. Although these data might raise serious concerns about the potentially harmful effects of transfusing patients with HF, there are important...
limitations in the analysis of this database. For example, the severity of anemia and clinical reasons for which a transfusion was required were not available and adjusted for. These and other residual measured and unmeasured confounders could have affected the results of the multivariable analysis. Prospective randomized controlled trials (RCTs) are required to clarify the role of packed RBC transfusions in patients with anemia and HF. Nevertheless, the TRICS III trial (Transfusion Requirements in Cardiac Surgery) in moderate- to high-risk patients undergoing cardiac surgery recently found that the composite primary outcome of death resulting from any cause, myocardial infarction (MI), stroke, and new-onset renal failure with dialysis occurred in 11.4% of those randomized to receive intraoperative or postoperative transfusions for hemoglobin <7.5 g/dL compared with 12.5% in the more liberal strategy of transfusions for hemoglobin <9.5 g/dL, indicating that, in such patients, a restrictive transfusion strategy is noninferior to a liberal strategy.43 These findings suggest that packed RBC transfusion in patients with HF and anemia is not necessarily beneficial and may even be associated with worse outcomes. Routine blood transfusion in asymptomatic patients, particularly those with nonacute anemia, therefore cannot be recommended.4 Because the hemoglobin threshold for packed RBC transfusions varies between clinical practice guidelines (summarized by Goodnough and Schrier10), careful consideration of individual factors, including age, comorbidities, and need for surgical intervention, is advisable when determining clinical indications for transfusion in patients with HF.

In the routine treatment of anemia, identification and correction of hematocin deficiencies (iron, B12, or folate) or hypothyroidism, if present, should clearly be the first step. However, because many patients are thought to have anemia of chronic disease, stimulating erythropoiesis with ESAs has been investigated.

**TREATMENT WITH ESAS**

Between 2000 and 2010, 13 small uncontrolled or randomized placebo-controlled studies tested the effects of increasing hemoglobin with ESAs (summarized in Table I in the online-only Data Supplement). Most studies found symptomatic improvement with use of ESAs. In 2011, Kotecha and colleagues published a meta-analysis based on 11 of these RCTs of 794 patients comparing any ESA with placebo with 2 to 12 months of follow-up. Nine studies were placebo controlled and 5 were double-blind. Five studies used epoetin and 6 used darbepoetin. ESAs improved exercise duration by 96.8 seconds (P=0.04) and 6-minute walk distance (6MWD) by 69.3 m (P=0.009) compared with controls (Figure I in the online-only Data Supplement). Significant changes were also observed in peak oxygen consumption (VO2; 2.29 mL·kg⁻¹·min⁻¹; P=0.007), New York Heart Association (NYHA) class (0.73; P<0.001), LVEF (5.8%; P<0.001), BNP (brain natriuretic peptide; –227 pg/mL; P<0.001), and QoL indicators with a mean increase in hemoglobin of 2 g/dL. HF-related hospitalizations were reduced by 44% (P=0.005) with ESA therapy, but the reduction in all-cause mortality (42%) was of borderline significance (P=0.047; Figure II in the online-only Data Supplement). Adverse effects of ESAs were rare, with no significant increase in the development of hypertension (odds ratio, 1.37; 95% confidence interval [CI] 0.65–2.87; P=0.41), stroke (odds ratio, 1.70; 95% CI, 0.52–5.62; P=0.38), MI (odds ratio, 0.67; 95% CI, 0.28–1.61; P=0.37), and thromboembolic events (odds ratio, 0.60; 95% CI, 0.17–2.11; P=0.43). In contrast, use of darbepoetin in patients with moderate to severe HFrEF was not associated with any increase in exercise capacity in STAMINA-HeFT (Study of Anemia in Heart Failure Trial), the largest (n=319) of these small studies.44

The encouraging results of these small studies were not supported by the large pivotal RED-HF trial, published in 2013.45 RED-HF was a double-blind placebo-controlled trial that randomized 2278 patients with HFrEF, NYHA class II to IV HF, LVEF ≤40%, and mild to moderate anemia (hemoglobin, 9.0–12.0 g/dL) receiving guideline-recommended HF therapy. Patients with ID defined as a transferrin saturation (TSAT) of <15%, unless corrected, were ineligible. Patients with a history of bleeding or other correctable causes of anemia, serum creatinine >3 mg/dL, or blood pressure >160/100 mmHg were excluded. Patients were randomized 1:1 to receive either darbepoetin alfa to achieve a hemoglobin target of 13 g/dL or placebo. Patients in the darbepoetin group received a starting dose of 0.75 μg/kg every 2 weeks until a hemoglobin of 13.0 g/dL was reached on 2 consecutive visits. Thereafter, patients received monthly darbepoetin to maintain a hemoglobin of 13.0 g/dL but not exceeding 14.5 g/dL. Iron indexes were assessed 3 monthly during the trial. If TSAT fell below 20%, oral and, if necessary, intravenous iron was administered. Patients had a median age of 72.0 years; 41% were women; 65% had NYHA class III or IV HF; the median LVEF was 31%; and the median estimated glomerular filtration rate was 45.7 mL·1.73 m² body surface area. Baseline median hemoglobin was 11.2 g/dL in both groups. One month after randomization and throughout the study thereafter, median attained hemoglobin remained ≥1.5 g/dL higher in the darbepoetin group (13.0 g/dL; interquartile range, 12.4–13.4 g/dL) compared with the placebo group (11.5 g/dL; interquartile range, 10.7–12.2 g/dL; P<0.001). After a median follow-up of 28 months, darbepoetin had no effect on the primary composite outcome of death resulting from any cause or hospitalization for worsening HF (hazard ratio [HR] 1.01; 95% CI, 0.90–1.13; P=0.87)
or on its individual components. The lack of any effect of darbepoetin was consistent across all prespecified subgroups examined; no subgroup experienced any benefit from darbepoetin. There was also no significant difference in any secondary outcome, including fatal or nonfatal MI, fatal or nonfatal strokes, hypertension, and HF. More patients had fatal or nonfatal strokes in the darbepoetin than in the placebo group, although the difference was not significant. This finding becomes important because thromboembolic adverse events were significantly higher in the darbepoetin (13.5%) compared with the placebo (10.0%; \( P=0.01 \)) group. Cancer-related adverse events were similar in the 2 groups. Although the rate of clinical events was not reduced by darbepoetin, treatment of anemia improved the Overall Summary and Symptom Frequency scores on the Kansas City Cardiomyopathy Questionnaire. However, the average between-group difference and the difference in the proportion of patients with a clinically meaningful improvement in these scores were of questionable importance. It is important to emphasize that all patients were iron repleted at baseline. The darbepoetin group received more iron during the study because of greater iron requirement for erythropoiesis. Neither group became ID during the study.

In summary, this large pivotal trial failed to confirm the results of previous smaller studies that treating mild to moderate anemia in patients with HFREF with ESAs improved clinical outcomes. Although an increase in hemoglobin was associated with a modest improvement in QoL, this was of questionable importance, particularly because the use of darbepoetin was associated with a significant increase in thromboembolic events. Similar findings in CKD and cancer populations for cardiovascular safety have raised concerns about the use of ESAs to increase hemoglobin to relatively higher levels. Therefore, a brief examination of the CKD data may be helpful.

### Are There Real Risks of Increasing Hemoglobin With ESA Therapy?

In the 1990s, several trials were conducted to assess whether complete normalization of hemoglobin with ESAs would produce additional benefits in patients with CKD. NHCT (Normal Hematocrit Cardiac Trial) randomized 1223 patients with CKD on hemodialysis to epoetin-alfa to achieve a hematocrit of 45% versus 30%. The study was terminated early because of a trend to an increase in the relative risk of mortality (34%; \( P=0.14 \)) with higher hemoglobin. The CHOIR trial randomized 1432 patients (hemoglobin, 10.1±0.9 g/dL) to epoetin to achieve a hemoglobin of 13.5 or 11.3 g/dL. The trial was stopped early for presumed futility but showed a 34% (\( P=0.03 \)) increase in the composite of death, MI, hospitalization for HF, and stroke in the high hemoglobin group. Subsequently, a meta-analysis of 9 randomized trials, including the 3 trials mentioned earlier, compared the low and high hemoglobin target strategies and found a relative increase in all-cause mortality of 17% (\( P=0.03 \)), arteriovenous access thrombosis of 34% (\( P=0.0001 \)), and poorly controlled blood pressure of 27% (\( P=0.004 \)) in the high hemoglobin groups.

With that background, TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy), the largest RCT, was designed to compare darbepoetin with placebo (achieved hemoglobin, 12.5 versus 10.6 g/dL) in 4038 patients with diabetes mellitus and CKD. Unlike previous trials that compared using ESA to achieve a high or a low hemoglobin, TREAT tested the more appropriate strategy of comparing an ESA with placebo. Darbepoetin had a neutral effect on the 2 primary composite outcomes (death or a cardiovascular event; death or a renal event) but was associated with a doubling of the risk of stroke. In a post hoc analysis of the TREAT trial of 1347 patients (33.4%) with HF at baseline, darbepoetin also had a neutral effect on all-cause mortality (HR, 1.10; 95% CI, 0.93–1.29) or nonfatal HF events (HR, 1.02; 95% CI, 0.87–1.20), similar to the entire cohort. Therefore, increasing hemoglobin to relatively higher levels in patients with CKD is associated with either neutral or deleterious effects on cardiovascular morbidity and mortality with increases in thrombotic and stroke risk. Consequently, the current (2017) US Food and Drug Administration–approved label for ESAs carries Black Box statements for patients with CKD:

- **(a)** In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target a hemoglobin level of greater than 11 g/dL.
- **(b)** No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks, and
- **(c)** Use the lowest ESA dose sufficient to reduce the need for RBC transfusions.

Consistent with the aforementioned guidance, Kidney Disease Outcomes Quality Initiative guidelines recommend interrupting or holding ESAs at a hemoglobin of 11.0 g/dL in patients with CKD. The US Food and
Drug Administration and the Kidney Disease: Improving Global Outcomes guidelines recommend initiating ESA therapy at a hemoglobin cutoff of <10 g/dL in patients with CKD on dialysis and individualizing ESA initiation at this level in patients with CKD not on dialysis, although the rationale for initiating ESAs at hemoglobin <10 g/dL rather than an even lower hemoglobin is not entirely clear if the only indication is to avoid transfusions. However, in a subgroup analysis of 816 TREAT-like patients with CKD and diabetes mellitus in RED-HF with baseline hemoglobin 11.0±0.8 g/dL, the use of darbepoetin to raise hemoglobin had an overall neutral effect on mortality (HR, 0.89; 95% CI, 0.73–1.09) but was associated with a 2-fold increase in stroke risk (HR, 2.07; 95% CI, 0.98–4.38), supporting the US Food and Drug Administration and Kidney Disease: Improving Global Outcomes guidelines on interrupting/holding ESAs at an upper level of hemoglobin ≥11 g/dL.

The overall consequences of correcting anemia in HF with ESAs are a tradeoff between the favorable effects of improving oxygen delivery and the putative cardioprotective effects of ESAs and the unfavorable effects of higher hemoglobin on increasing viscosity, vascular resistance, and blood pressure and of ESAs on hypercoagulability. Moreover, the starting, achieved, change-in, and rates of rise in hemoglobin and the dose of ESA may influence the net effect of treatment.

Taken together, data from small, short-term trials and meta-analyses of ESA in HF and the pivotal RED-HF trial suggest that correcting anemia with ESAs does not improve outcomes but does increase the risk of thromboembolic events. The findings do not support the use of these agents to increase hemoglobin in patients with HFrEF and mild to moderate anemia to higher levels. Therefore, although HF guidelines recommend a diagnostic workup to seek and treat correctable causes of anemia, they provide a Class III (no benefit), Level of Evidence BR recommendation: “In patients with HF and anemia, ESAs should not be used to improve morbidity and mortality.”

Iron Deficiency and HF

Normal Iron Metabolism and Homeostasis

Iron is the most important essential trace element in the body. Apart from its role in maintaining the oxygen-carrying capacity of the blood through erythropoiesis, iron is independently crucial for oxygen transport, delivery, and utilization. It is a key component of hemoglobin, myoglobin, and diverse enzymes involved in cellular respiration, oxidative phosphorylation, citric acid cycle, nitric oxide generation, oxygen radical production, and several critical body functions. Metabolic active cells, including myocytes and skeletal muscle cells, are dependent on iron for their function and structural integrity. Iron distribution and metabolism in healthy individuals are illustrated in Figure 2.

Iron Deficiency in HF

ID is a very common comorbidity in HF regardless of sex, race, anemia, and LVEF. Overall, nearly 50% of patients with HF with or without anemia have low levels of available iron. ID can be absolute, when total body iron is decreased, or functional, when total body iron is normal or increased but inadequate to meet the needs of target tissues because of sequestration in the storage pool (iron maldistribution; Figure 3).

Diagnosis of ID

In the absence of inflammation or chronic disease, serum ferritin correlates strongly with body iron stores: 1 μg/L serum ferritin corresponds to ~10 mg tissue iron. Serum ferritin of 100 μg/L thus reflects ~1 g tissue iron stores. In healthy individuals, ferritin below ~30 μg/L and TSAT below ~16% define ID. In inflammatory states (including HF), however, ferritin is nonspecifically elevated as an acute-phase reactant, making identification of absolute or functional ID complex and uncertain. Consequently, in patients with HF, ferritin <100 μg/L or <300 μg/L if TSAT is <20% has been used to include patients with both absolute and functional ID in iron replacement trials.

Table 1 summarizes tests available to diagnose ID. The soluble transferrin receptor (sTfR) level is increased in ID and is not affected by inflammation. Among the blood parameters, sTfR or TSAT may have the strongest correlation with bone marrow iron depletion. Although not commonly available in clinical practice, sTfR, sTfR/log(ferritin) ratio, or hepcidin levels may provide better discrimination of absolute and functional ID. Improving the diagnostic accuracy of tests to identify ID remains an area of active investigation.

Bone Marrow Iron Content for the Diagnosis of ID

Bone marrow iron depletion is very specific for ID, is not influenced by inflammation, and remains the gold standard for the definitive diagnosis of ID. However, its clinical applicability is limited because its assessment is invasive, expensive, somewhat subjective (relying on staining and observer interpretation), and difficult to perform serially. Few studies have correlated bone marrow iron with blood parameters of ID in HF. One small study in 37 hospitalized patients with decompensated HF and anemia found depleted bone marrow iron in 73% of patients despite normal serum iron, ferritin, and erythropoietin. Unpredictable and inconsistent
variability in measured levels of ferritin and TSAT may partly explain discrepancies between blood parameters and bone marrow iron. Recently, Grote Beverborg and colleagues examined bone marrow iron in a relatively small cohort of 42 patients with HFrEF undergoing coronary artery bypass surgery and found bone marrow ID in 17 patients (40%). The commonly used definition of ID (ferritin <100 µg/L or 100–300 µg/L with TSAT <20%) had a sensitivity of 82% and a specificity of 72% for true ID. As single parameters, TSAT ≤ 19.8% and serum iron ≤ 13 µmol/L (≤ 72.6 µg/dL) were highly correlated with absolute or functional bone marrow ID (sensitivity, 94% for both; specificity, 84% and 88%, respectively; P<0.05). TSAT was calculated with the use of transferrin rather than total iron-binding capacity in the denominator (thus, TSAT=iron/transferrin). It is notable that patients with low ferritin (<100 ng/mL) but normal TSAT (>20%) did not have bone marrow ID. In 387 patients with HF, TSAT or serum iron (but not ferritin) below these cutoffs was independently associated with higher all-cause mortality (P=0.015 and P=0.022, respectively), underscoring their prognostic significance. An individual patient data meta-analysis of 4 clinical trials (n=839) of the effects of intravenous ferric carboxymaltose (FCM) in patients with HFrEF found that TSAT ≤ 19.8% (but not serum iron [interaction P=0.077]) or
Iron deficiency can be absolute, when total body iron is decreased, or functional, when total body iron is normal or increased but sufficient iron is not available to target tissues because of iron sequestration in the storage pool (iron maldistribution). Both storage and functional pools are smaller in absolute iron deficiency, whereas only the functional pool is reduced in functional iron deficiency. Either condition can occur independently or coexist in an individual patient. Absolute iron deficiency in HF can result from reduced intake because of anorexia, cardiac cachexia, impaired iron absorption resulting from intestinal edema, and (Continued)
ferritin) identified patients who experienced reduction in cardiovascular hospitalizations and mortality (risk reduction 0.45 [95% CI, 0.29–0.71] versus 1.55 [95% CI, 0.69–3.47] for patients with TSAT >19.8%; interaction 0.45 [95% CI, 0.29–0.71] versus 1.55 [95% CI, 0.69–3.47]) for patients with TSAT >19.8%. Thus, although the conventional definition of ID (ferritin <100 µg/L or 100–300 µg/L with TSAT <20%) performs reasonably well in diagnosing ID in patients with HF, a single parameter (TSAT ≤19.8% alone) performed at least as well in detecting true ID and identified subjects who responded to intravenous FCM on retrospective analysis. Ferritin levels may be more relevant for monitoring iron overload rather than diagnosis of ID in patients with HF.

### Pathophysiological Consequences of ID

Although ID is associated with several clinical consequences related to erythropoiesis, chronic ID by itself, independently of anemia, impairs oxidative metabolism, cellular energetics, and immune mechanisms that can cause structural and functional change in the myocardium, decreasing oxygen storage in myoglobin and

---

**Table 1. Laboratory Tests Available for the Diagnosis of ID and Their Sensitivity and Specificity**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal Range*</th>
<th>Absolute Iron Depletion Without Anemia</th>
<th>Absolute ID With Anemia</th>
<th>Functional ID Without or With Anemia</th>
<th>Sensitivity, %†</th>
<th>Specificity, %†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow iron stores</td>
<td>Normal</td>
<td>Absent from both erythroid progenitors and reticuloendothelial cells</td>
<td>Absent from both erythroid progenitors and reticuloendothelial cells</td>
<td>Low in erythroid progenitors, normal in reticuloendothelial cells</td>
<td>Gold standard</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin, g/dL</td>
<td>M: 13.5–17.5; F: 12.0–15.5</td>
<td>N</td>
<td>↓↓</td>
<td>N/↓</td>
<td>Poor</td>
<td>Poor</td>
</tr>
<tr>
<td>Mean red cell volume, fl</td>
<td>M: 81–95; F: 82–98</td>
<td>N/↓</td>
<td>↓↓</td>
<td>N/↓</td>
<td>Poor</td>
<td>88.3</td>
</tr>
<tr>
<td>Ferritin, µg/L</td>
<td>M: 24–336; F: 11–307</td>
<td>=20</td>
<td>↓15–30</td>
<td>N/↑</td>
<td>35–48</td>
<td>75–100</td>
</tr>
<tr>
<td>Serum iron, µg/dL‡</td>
<td>M: 50–150; F: 35–145</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>Poor</td>
<td>Poor</td>
</tr>
<tr>
<td>Total iron binding capacity, µg/dL, or transferrin, mg/dL</td>
<td>250–400; 200–360</td>
<td>N</td>
<td>↑</td>
<td>N/↓</td>
<td>Poor</td>
<td>Poor</td>
</tr>
<tr>
<td>TSAT, ‰†</td>
<td>≤15–50</td>
<td>≥30</td>
<td>&lt;15</td>
<td>N/↓</td>
<td>59–88</td>
<td>63–78</td>
</tr>
<tr>
<td>sTfR, mg/L§†</td>
<td>1.8–4.6</td>
<td>↑</td>
<td>↑↑</td>
<td>↑</td>
<td>70–81</td>
<td>59–71</td>
</tr>
<tr>
<td>sTfR/log(ferritin) ratio</td>
<td>≤1.03†</td>
<td>↑</td>
<td>↑↑</td>
<td>↑</td>
<td>81</td>
<td>83</td>
</tr>
<tr>
<td>Hepcidin, ng/mL§‡</td>
<td>M: 29–254; F: 17–286</td>
<td>N</td>
<td>↓</td>
<td>↑</td>
<td>50–92.5</td>
<td>85–90</td>
</tr>
<tr>
<td>ZPP, µmol ZPP/mol hemoglobinα‡</td>
<td>&lt;70</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>38</td>
<td>87</td>
</tr>
<tr>
<td>Hypochromic RBC, %</td>
<td>&lt;2.5</td>
<td>N/↑</td>
<td>↑</td>
<td>N/↑</td>
<td>64–78</td>
<td>77–78</td>
</tr>
<tr>
<td>CHr, pg</td>
<td>≥28–35</td>
<td>N/↑</td>
<td>↓</td>
<td>N/↓</td>
<td>53–78</td>
<td>53–100</td>
</tr>
</tbody>
</table>

CHr indicates reticulocyte hemoglobin content; F, female; ID, iron deficiency; M, male; MCV, mean red cell volume; N, normal; NA, not available; RBC, red blood cells; RES, reticuloendothelial cell; sTfR, soluble transferrin receptor; TIBC, total iron binding capacity; TSAT, transferrin saturation; and ZPP, red cell zinc protoporphyrin.

*The normal ranges for various parameters may vary in individual laboratories.
†Data from von Haehling and colleagues65 or as otherwise referenced.
‡Grote Beverborg and colleagues69 reported that the sensitivity and specificity (as single parameters) of TSAT were 94% and 84%, respectively, and for serum iron were 94% and 88%, respectively, for absolute or functional ID, confirmed by bone marrow examination in patients with heart failure undergoing coronary artery bypass grafting.
§Jankowska and colleagues70 reported that the sensitivity and specificity of sTfR were 67% and 97%, respectively, for ID confirmed by bone marrow examination in patients with coronary artery disease.
| These tests may not be routinely available in clinical laboratories.
reducing tissue oxidative capacity, leading to mitochondrial and LV dysfunction.76-77 Myocardial iron stores may be depleted in HF but correlate poorly with circulating markers of iron stores.78 Melenovsky and colleagues55 found that myocardial iron content in 91 patients with HF was lower than in 38 normal control organ donors (156±41 versus 200±38 µg/g dry weight, respectively; P<0.001). Reduced myocardial iron correlated with lower activity of citric acid cycle enzymes (aconitase and citrate synthase); diminished reactive oxygen species (ROS) protecting enzymes, including catalase, glutathione peroxidase, and superoxide dismutase; and reduced mitochondrial oxygen consumption. Myocardial ID in patients with HF might therefore further promote glucose rather than fatty acid utilization and, coupled with impaired protection against ROS, contribute to myocardial dysfunction and adverse remodeling. That severe myocardial ID can cause mitochondrial dysfunction is supported by the observation that isolated cardiac ID (induced by myocardial transferrin receptor 1 inactivation) induces mitochondrial respiratory dysfunction and fatal cardiomyopathy in mice.79 Iron supplementation partly prevented these adverse effects, suggesting a possible mechanism for the clinical benefit of intravenous iron in patients with HF (discussed below).

**Impact of ID on Exercise Capacity, QoL, and Outcomes**

Several studies showed that ID in patients with HF is associated with reduced exercise capacity, impaired QoL, and poor prognosis independently of anemia and LV EF.58,60,80,81 In a prospective study on 443 patients with stable HF and a mean LV EF of 26%, ID (serum ferritin <100 µg/L or 100–300 µg/L with TSAT <20%) was present in 35%. Peak VO₂ was significantly lower in those with ID compared with those without ID (peak VO₂, 13.3±4.0 versus 15.3±4.5 mL·min⁻¹·kg⁻¹). In multivariable models, ID was associated with reduced peak VO₂ independently of demographics and clinical variables, including anemia.80

Several observational studies have shown that the presence of ID in patients with HF with and without anemia is significantly associated with mortality independently of other prognostic factors.57,60,82 In 546 Polish patients with HF, absolute or functional ID (ferritin <100 µg/L or 100–300 µg/L with TSAT <20%) was present in 37% of patients; 57% were anemic and 32% were not anemic.82 On multivariable analysis, ID but not anemia remained a strong independent predictor of mortality in multivariable models that included NYHA class and NT-proBNP (HR, 1.42; 95% CI, 1.14–1.77; P=0.002),60 underscoring the importance of ID over anemia in predicting outcomes in HF. Similar findings were reported in an Asian cohort.57 Adverse effects of ID on exercise capacity in patients with HF may therefore be a consequence of the nonhematopoietic (rather than erythroid) effects of iron on energy metabolism and myocardial structure and function.76-79 This possibility needs to be examined prospectively.

**INTRAVENOUS IRON REPLACEMENT THERAPY IN HF**

Although the role of ID in HF pathogenesis is only just being clarified, investigators have been testing the safety and efficacy of intravenous iron in patients with HFrEF and ID for >10 years. As of 2017, 8 studies (2 small uncontrolled studies and 6 RCTs [3 small and 3 medium-sized trials]) reported the effects of intravenous iron in patients with HFrEF (Table II in the online-only Data Supplement). The primary objective of these studies was to investigate the safety and efficacy of intravenous iron on exercise capacity, NYHA class, and QoL. Clinical events were recorded as safety and secondary outcomes. Five studies (n=103 patients) used intravenous iron sucrose; 3 studies (n=504) used FCM. Therefore, the highest level of evidence for the safety and efficacy of intravenous iron therapy in patients with HFrEF and ID is with FCM. Four meta-analyses of published data reported the effects of intravenous iron on the secondary outcomes of HF hospitalizations and mortality.83-86 In addition, a robust meta-analysis of intravenous FCM on mortality and hospitalizations using individual patient data extracted from 4 RCTs, including data from 2 small previously unreported studies (FER-CARS-01 and EFFICACY-HF [Effect of Ferric Carboxymaltose on Exercise Capacity and Cardiac Function in Patients With Iron Deficiency and Chronic Heart Failure]), has recently been published.87

Bolger and colleagues88 first reported an uncontrolled open-label study of 16 anemic (hemoglobin ≤12 g/dL) patients with HF given intravenous iron sucrose for 12 to 17 days and followed up for 92±6 days. Iron treatment increased serum iron, ferritin, TSAT, and hemoglobin (11.2±0.7–12.6±1.2 g/dL; P=0.0007) and improved NYHA class, Minnesota Living With Heart Failure Questionnaire score, and 6MWD. In another open-label study, intravenous iron sucrose treatment in 32 patients with anemia and ID was associated with favorable effects on LV remodeling and NYHA functional class.89

The first randomized study was a double-blind, placebo-controlled trial in 40 anemic patients with HF.90 Twenty control subjects received intravenous saline and 20 received 200 mg intravenous iron sucrose.
weekly for 5 weeks. After 6 months, hemoglobin increased by a mean of 1.4 g/dL (P<0.01), and there was improvement in creatinine clearance and Minnesota Living With Heart Failure Questionnaire score, a decrease in C-reactive protein and NT-proBNP, and an increase in LVEF and 6MWD in the intravenous iron but not placebo group. FERRIC-HF (Ferric Iron Sucrose in Heart Failure)\textsuperscript{91} was the first trial to use an inclusion criterion of ID defined as ferritin <100 μg/L or 100 to 300 μg/L with TSAT <20%. This definition of ID has since been used in all subsequent trials. Eighteen anemic (hemoglobin, <12.5 g/dL) and 17 non-anemic (hemoglobin, 12.5–14.5 g/dL) patients with ID and peak $V_O_2 \leq 18 \text{ mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ were randomized to open-label, observer-blinded treatment with placebo or intravenous iron sucrose 200 mg/wk for 4 weeks during the initial ID correction phase (using the Gonzoni formula; Table 2) and additional iron sucrose 200 mg/mo as required during the maintenance phase or to no treatment for the next 3 months. The iron requirement was higher in patients with anemia than in those without anemia (1051 versus 781 mg). Iron therapy increased serum ferritin and improved NYHA class, but unlike the previous 2 studies, hemoglobin did not increase. Peak $V_O_2$ increased significantly in anemic but not in nonanemic patients.

FAIR-HF (Ferinject Assessment in Patients With Iron Deficiency and Chronic Heart Failure) is the largest randomized study reported so far.\textsuperscript{92} Patients (n=459) with HF and ID (ferritin <100 μg/L or 100–300 μg/L with TSAT <20%), with anemia (hemoglobin 9.5–12.0 g/dL) or without anemia (hemoglobin 12.0–13.5 g/dL), were randomly assigned 2:1 to intravenous FCM (n=304) or placebo (saline; n=152). FCM significantly improved the primary end point of 6MWD at week 24 compared with placebo, a benefit sustained at 1 year. This was associated with significant improvements in secondary end points, including NYHA class, patient global assessment, QoL, and fatigue score. FCM treatment was also associated with a significant reduction in the risk of hospitalizations for worsening HF (HR, 0.39; 95% CI, 0.19–0.82; P=0.009) with no difference in all-cause mortality. These findings indicate that the benefits of FCM on functional capacity, symptoms, and QoL in symptomatic, iron-deficient patients with HF are sustainable over a 1-year period. Unlike previous studies, CONFIRM-HF\textsuperscript{95} also showed that the use of intravenous iron may be associated with a reduction in the risk of hospitalization for worsening HF.

The most recent study, EFFECT-HF (Effect of Ferric Carboxymalate on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure),\textsuperscript{96} randomized 172 patients with HF/EF and ID (ferritin <100 μg/L or 100–300 μg/L if TSAT <20%), NYHA class II to III HF, LVEF <45%, BNP >100 pg/mL or NT-proBNP >400 pg/mL, hemoglobin <15 g/dL, and peak $V_O_2$ of 10 to 20 mL·kg\textsuperscript{-1}·min\textsuperscript{-1} to FCM (n=86) or standard care (n=86, who could receive oral iron as needed). At 24 weeks, the primary end point of change in peak $V_O_2$ from baseline was no different between the FCM and control groups ($\Delta V_O_2 = −0.16±0.373 \text{ mL} \cdot \text{min}^{-1} \cdot \text{kg}^{-1}$ in those receiving FCM and $−0.63±0.375 \text{ mL} \cdot \text{min}^{-1} \cdot \text{kg}^{-1}$ in controls; P=0.23) in an analysis in which missing data were not imputed. Patients’ global assessment and functional (NYHA) class improved on FCM versus standard care. Outcomes were not assessed.

The meta-analysis by Anker and colleagues\textsuperscript{87} explored the effects of intravenous iron on objective cardiovascular outcomes and was reported before the results of EFFECT-HF were available. The authors examined individual patient data extracted from 4 RCTs comparing FCM with placebo in 839 patients with HFrEF and ID, 504 randomized to pooled FCM and 335 to pooled placebo groups. Approximately 90% of the patients were contributed by FAIR-HF and CONFIRM-HF. Patients in the 4 RCTs had very similar baseline characteristics; the same criteria were used to diagnose ID; and the same intravenous iron therapy (FCM) was tested. Therefore, this meta-analysis provides a more accurate and robust assessment of the relative effects of FCM on hard clinical outcomes compared with other recently performed meta-analyses that used different criteria for diagnosing ID, used different intravenous preparations, and included patients prescribed ESAs.\textsuperscript{83–86} The main finding of the Anker et al\textsuperscript{87} meta-analysis is that FCM treatment is associated with lower rates of recurrent cardiovascular hospitalizations and cardiovascular mortality (rate ratio, 0.59; 95% CI, 0.40–0.88; P=0.009), recurrent HF hospitalizations and cardiovascular mortality (rate ratio, 0.53; 95% CI, 0.33–0.86; P=0.011), and recurrent cardiovascular hospitalizations and all-cause mortality (rate
Iron toxicity.94 A complex that makes iron available in a controlled manner after uptake and regulated export by reticuloendothelial cells and releases less labile iron that could cause

<table>
<thead>
<tr>
<th>Iron Preparation</th>
<th>Maximal Single Dose in Adults*</th>
<th>Administration in Adults*</th>
<th>Indications*</th>
<th>Most Common Adverse Effects</th>
<th>Evaluated in Heart Failure†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferric carboxymaltose</td>
<td>750 mg.</td>
<td>Slow intravenous push at 100 mg/min or diluted in normal saline and infused over at least 15 min.</td>
<td>Treatment of ID anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have non-dialysis-dependent chronic kidney disease.</td>
<td>Nausea, hypotension, flushing, hypophosphatemia, and dizziness. Warnings: hypersensitivity reactions, hypertension.</td>
<td>Yes</td>
</tr>
<tr>
<td>Iron sucrose</td>
<td>100–400 mg, depending on clinical setting. Limited experience with 500 mg. Doses can be repeated at various intervals, depending on setting. Courses can be repeated if ID recurs.</td>
<td>Slow intravenous injection of 100–200 mg over 2–5 min. Infusion schedules vary depending on dose and setting.</td>
<td>Treatment of ID anemia in patients with chronic kidney disease.</td>
<td>Diarrhea, nausea, vomiting, headache, dizziness, hypotension, pruritus, pain in extremity, arthralgia, back pain, muscle cramp, injection site reactions, chest pain, and peripheral edema. Warnings: hypersensitivity reactions, hypotension, iron overload.</td>
<td>Yes</td>
</tr>
<tr>
<td>Sodium ferric gluconate</td>
<td>125 mg (adults), 1.5 mg/kg (pediatric patients).</td>
<td>Adults: slow intravenous injection at 12.5 mg/min or diluted in normal saline and infused over 1 h per dialysis. Pediatric patients: dose diluted in normal saline and infused over 1 h per dialysis.</td>
<td>Treatment of ID anemia in adult patients and in pediatric patients ≥6 y of age with chronic kidney disease receiving hemodialysis who are receiving supplemental erythropoietin therapy.</td>
<td>Nausea, vomiting and/or diarrhea, injection site reaction, hypotension, cramps, hypertension, dizziness, dyspnea, chest pain, leg cramps, and pain. In patients 6–15 y of age: hypotension, headache, hypertension, tachycardia, and vomiting. Warnings: hypersensitivity reactions, hypotension, iron overload.</td>
<td>No</td>
</tr>
<tr>
<td>Ferumoxytol</td>
<td>510 mg. Second 510-mg dose 3–8 d later.</td>
<td>Diluted in normal saline or 5% dextrose and infused over at least 15 min.</td>
<td>Treatment of ID anemia in adults with chronic kidney disease.</td>
<td>Diarrhea, nausea, dizziness, hypotension, and constipation. Black Box warning: fatal and serious hypersensitivity reactions, including anaphylaxis.</td>
<td>No</td>
</tr>
<tr>
<td>Iron dextran</td>
<td>100 mg daily. Total dose calculated on the basis of body iron deficit.</td>
<td>Slow intravenous injection not to exceed 50 mg/min.</td>
<td>Treatment of ID anemia when oral administration is unsatisfactory or impossible.</td>
<td>Most common side effects not separately listed in the label. Black Box warning: fatal and serious hypersensitivity reactions, including anaphylaxis.</td>
<td>No</td>
</tr>
<tr>
<td>Iron isomaltoside†</td>
<td>20 mg iron/Kg. Cumulative dose based on Ganzoni formula.</td>
<td>Intravenous injection not to exceed 250 mg iron/min; dose ≤500 mg 3 times a week; diluted in normal saline. Intravenous infusion: diluted in normal saline and infused over 15 min (dose ≤1000 mg) or 30 min (dose &gt;1000 mg).</td>
<td>Treatment of ID when oral iron preparations are ineffective or cannot be used or when there is a clinical need to deliver iron rapidly. Not recommended for age &lt;18 y.</td>
<td>Nausea, injection site reactions. Special warnings and precautions: hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions. Administer with caution/avoid in patients with liver dysfunction or acute/chronic infection. Hypotension if infused too rapidly. Injection site irritation or discoloration with leakage.</td>
<td>No</td>
</tr>
</tbody>
</table>

ID indicates iron deficiency.

There are several potential advantages of intravenous vs oral iron: it can be administered in a few doses; it rapidly restores iron stores even in the presence of inflammatory conditions; it causes fewer gastrointestinal side effects; and it does not depend on patient adherence/compliance. However, intravenous iron preparations are considerably more expensive, require facilities equipped for cardiopulmonary resuscitation because they can cause potentially fatal hypersensitivity reactions, and can cause iron overload if not appropriately monitored.

*According to the regulatory agency-approved drug label. Total body iron deficit, and therefore the total iron dose required, can be estimated with the Ganzoni formula: body weight x (15−Hb)/2.4+iron stores. Clinically, however, dose and frequency of administration are usually determined by product labels, local protocols, and indication for treatment. Adequacy of replacement is assessed by improvement in hemoglobin, ferritin, and transferrin saturation.

†In patients with heart failure, the highest level evidence is available for the use of ferric carboxymaltose.99,100 Furthermore, ferric carboxymaltose can be administered at a relatively large dose (750 mg) over a short period (7.5 min) because it is a stable, high-molecular-weight polynuclear iron (III) hydroxide carbohydrate complex that makes iron available in a controlled manner after uptake and regulated export by reticuloendothelial cells and releases less labile iron that could cause iron toxicity.101†Approved in Europe but not in the United States.
Intravenous Iron Preparations

Parenteral iron preparations (Table 2) have seen enormous development over the past 20 years. At present, 5 intravenous iron preparations are available in the United States and Europe, of which 2 preparation (iron sucrose and FCM) have been tested prospectively in patients with HF. In addition, iron isomaltoside is available in Europe but not yet in the United States. Both iron isomaltoside and FCM enable higher doses of iron to be administered to replenish iron stores more rapidly.

Oral Iron Replacement Therapy in HF

Although oral iron supplementation is convenient, readily available, and inexpensive, oral iron is not absorbed well, particularly in patients with HF because of effects of HF on the gastrointestinal tract and elevated hepcidin, which inhibits iron absorption by reducing transmembrane ferroportin on enterocytes, thereby reducing iron transfer from enterocytes to blood.97 Moreover, oral iron is associated with adverse effects, particularly gastrointestinal intolerance, that limit compliance. Few studies have investigated the effects of oral iron in patients with ID and HF.98 The results of IRONOUT HF (Iron...
Repletion Effects on Oxygen Uptake in Heart Failure), the largest randomized study to examine the effects of high-dose oral iron in patients with HF, was published recently. In this phase 2 double-blind RCT, 225 patients with NYHA class II to IV HF (median LVEF, 25%), hemoglobin of 9 to 15 g/dL (men) or 9 to 13.5 g/dL (women), and ID (ferritin 15–100 µg/L or 100–299 µg/L with TSAT <20%) received either oral iron polysaccharide 150 mg twice daily or placebo. At 16 weeks, there was no significant difference between the groups in the primary end point of change in peak VO2 from baseline or in any secondary end point (6MWD, NT-proBNP levels, or Kansas City Cardiomyopathy Questionnaire score), although oral iron increased TSAT, ferritin, and hepcidin and reduced stFtR-1 levels. These findings contrast with the results from trials of intravenous iron therapy in similar patient populations. Reasons for a lack of response to oral iron are not entirely clear. Robust repletion of iron stores may be required to achieve clinical benefit because oral iron induced only modest iron repletion (median increases from baseline in TSAT of 3% and ferritin of 11 µg/L in IRONOUT HF), in contrast to median increases of 11.3% and 259.5 µg/L, respectively, with intravenous iron in FAIR-HF. This modest repletion of iron stores occurred despite 15-fold more oral iron administered in IRONOUT HF compared with intravenous iron in FAIR-HF (33.6 versus ≈2 g). Patients with higher baseline hepcidin levels demonstrated less improvement in TSAT and ferritin and an attenuated decline in stFtR levels, suggesting that higher hepcidin levels may limit responsiveness to oral iron, perhaps via inhibiting duodenal iron absorption.

In summary, these early studies provide encouraging data raising the possibility that intravenous but not oral iron therapy has a potential role in patients with HFrEF and absolute or functional ID with or without anemia. Most studies found that intravenous iron improved exercise capacity, NYHA class, and QoL. Although no study by itself showed significant improvements in cardiovascular mortality, meta-analyses of 4 trials demonstrated significant improvements in objective cardiovascular outcomes. Overall, intravenous iron was safe in the short term, but data on long-term safety and efficacy are lacking. Nevertheless, the 2016 European Society of Cardiology guidelines interpreted the available data as being adequate to provide a Class IIa, Level of Evidence A recommendation: “Intravenous FCM should be considered in symptomatic patients with HFrEF and iron deficiency (serum ferritin <100 µg/L, or ferritin 100–299 µg/L and TSAT <20%) in order to alleviate HF symptoms, and improve exercise capacity and quality of life.” The 2017 American Heart Association/American College of Cardiology guidelines provide a lower Class IIb, Level of Evidence BR recommendation: “In patients with NYHA class II and III heart failure and iron deficiency (ferritin <100 µg/L or 100–300 µg/L if TSAT <20%), intravenous iron replacement might be reasonable to improve functional status and QoL.”

Despite these recommendations, long-term clinical studies are still required to confirm the beneficial effects of intravenous iron on outcomes; to provide additional safety data, particularly on the potential adverse effects of iron overload during long-term administration in patients with HF; and to determine which parameters best reflect iron stores to guide iron supplementation. Several large long-term studies examining cardiovascular outcomes are ongoing (Table III in the online-only Data Supplement). Some ongoing studies directly examining changes in myocardial iron content, gene expression, and skeletal muscle metabolism are also likely to provide critical insights into the pathophysiological role of ID in nonerythroid tissues and the clinical effects of its repletion in patients with HF. Data from these studies are likely to provide valuable information to guide clinical decision making.

POTENTIAL ADVERSE EFFECTS OF IRON OVERLOAD ON THE HEART

The human body does not possess any mechanism to excrete iron; instead, it regulates duodenal iron uptake. Above TSAT values of 70% to 85%, nontransferrin-bound iron is formed, part of which is called labile plasma iron or labile cellular iron. Labile plasma iron/labile cellular iron catalyzes free radical (ROS) formation, which damages mitochondria, lipids, proteins, and nucleic acids. Under normal physiological conditions, duodenal iron uptake of dietary iron is reduced to prevent iron overload, which could lead to formation of free/unbound iron. However, this protective mechanism is bypassed when iron is administered intravenously. Iron overload can cause cardiomyopathy and HF, increases the risk of bacteremia, and promotes ROS formation, which can cause widespread tissue damage and endothelial dysfunction. These effects may increase the risk of adverse cardiovascular outcomes. Several mechanisms of iron-induced cardiac damage have been described, mainly related to ROS formation, which leads to cardiac myocyte apoptosis, fibrosis, and HF. Myocardial cells have low levels of antioxidant enzymes, and ROS-protective enzyme levels are further reduced by myocardial ID in HF, potentially making the failing heart even more susceptible to iron-mediated damage. Labile plasma iron/labile cellular iron directly enters cardiomyocytes (primarily via L-type calcium channels), increases ROS production, and may inhibit calcium influx, which further adversely influences myocardial excitation-contraction coupling. Intravenous iron given repeatedly over long periods can lead to clinically relevant tissue iron overloading. For instance, the drug label for FCM describes iron overload–induced...
HEPCIDIN AS A POTENTIAL THERAPEUTIC TARGET IN HF WITH IRON DEFICIENCY

Hepcidin is the master regulator of iron absorption and distribution, and its level is increased in chronic diseases, including HF. Increased hepcidin reduces duodenal iron absorption and simultaneously reduces iron release from stores in reticulo-endothelial cells and hepatocytes, thereby causing functional ID (Figures 2 and 3). Blocking hepcidin might therefore be an effective therapeutic strategy, particularly in functional ID. In early human studies, several investigational antihepcidin agents increased iron bioavailability. Promising strategies include directly blocking hepcidin expression by an anti–hepcidin l–oligoribonucleotide (lexapetid) or its activity by a fully human anti-hepcidin antibody or blocking hepcidin signaling by a small-molecule inhibitor (LDN-193189) or nonanticoagulant heparrins.16,105 Spironolactone, commonly used in patients with HF, inhibits hepcidin expression in mice, raising the possibility that this drug may be repurposed to this end.106 Whether strategies that downregulate hepcidin will be of clinical benefit merits prospective evaluation.

CONCLUSIONS

Anemia and absolute or relative ID are common co-morbidities in patients with HF and are associated with poor clinical status and worse outcomes. Although the cause of anemia in HF is not entirely clear, evidence suggests that neurohormonal and proinflammatory cytokine activation and renal dysfunction favor the development of anemia of chronic disease. Whereas ESAs were considered to be a rational therapy to increase hemoglobin and to treat anemia in HF, these agents do not improve outcomes and may be associated with thromboembolic complications. ESAs are therefore not recommended.

Early data from short-term studies in patients with HFrEF and absolute or functional ID with or without anemia suggest that intravenous but not oral iron therapy may have a potential role in improving exercise capacity, NYHA class, and QoL. However, larger, adequately powered trials with cardiovascular mortality and morbidity end points are needed to establish the long-term efficacy and safety of intravenous iron in patients with HF. The numerous long-term ongoing studies are likely to provide valuable information to address these concerns and to help guide future clinical decision making.

ARTICLE INFORMATION

The online-only Data Supplement is available with this article at http://circ.aha-journals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.118.030099/-/DC1.

Correspondence

Inder Anand, MD, DPhil (Oxon), Professor of Medicine, 5448 Caminito Bayo, La Jolla, CA 92037. E-mail anand001@umn.edu

Affiliations


Acknowledgments

The authors thank Dr Hector Mesa (Minneapolis VA Medical Center and University of Minnesota) for critical review of the article and James Hungaski (Minneapolis VA Medical Center) for creating the original illustrations (Figures 1 through 3). The authors apologize to the many investigators whose work could not be discussed or cited because of space considerations.

Disclosures

None.

REFERENCES


Anemia and Iron Deficiency in Heart Failure

Iron deficiency is a common and significant complication of heart failure. The presence of iron deficiency in heart failure patients is associated with worse outcomes. The mechanisms linking iron deficiency and heart failure are complex and involve multiple factors such as inflammation, oxidative stress, and cardiomyocyte dysfunction. The treatment of iron deficiency in heart failure can improve outcomes and reduce morbidity and mortality. Further research is needed to fully understand the role of iron deficiency in heart failure and to develop effective treatment strategies.

References:


Additional references...
STATE OF THE ART

Anand and Gupta


Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies
Inder S. Anand and Pankaj Gupta

Circulation. 2018;138:80-98
doi: 10.1161/CIRCULATIONAHA.118.030099
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2018 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/138/1/80

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2018/07/02/CIRCULATIONAHA.118.030099.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL

Supplemental Table 1: Summary of Studies that Tested the Effects of ESAs in Patients with Anemia and Heart Failure.

Supplemental Table 2: Summary of Studies that Tested the Effects of Intravenous Iron in Patients with Anemia and Heart Failure.

Supplemental Table 3: Recently Completed and Ongoing Trials of Intravenous Iron Supplementation in Patients with Heart Failure (Registered with ClinicalTrials.gov).

Supplemental Figure 1: Effect of ESA Therapy on Hb, LVEF, Exercise Capacity and NYHA Class from the Meta-analysis of Phase II Randomized Controlled Studies.

Supplemental Figure 2: Effect of ESA Therapy on Hospitalizations for Heart Failure and All-Cause Mortality from the Meta-analysis of Phase II Randomized Controlled Studies.

References: For Supplemental Material.
**Supplemental Table 1: Summary of Studies that Tested the Effects of ESAs in Patients with Anemia and Heart Failure.**

<table>
<thead>
<tr>
<th>Author</th>
<th>Study Design</th>
<th>Inclusion Criteria</th>
<th>Patients (n)</th>
<th>Follow-up Duration</th>
<th>Baseline Hb (g/dL)</th>
<th>Target Hb (g/dL)</th>
<th>Achieved Hb (g/dL)</th>
<th>Agents and dose used</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silverberg¹ 2000</td>
<td>Single center, Uncontrolled Open label</td>
<td>LVEF &lt;35%, Hb &lt;12 g/dL</td>
<td>26</td>
<td>7.2 ± 5.5 months</td>
<td>10.2</td>
<td>12.0</td>
<td>12.1</td>
<td>S/C epoetin alfa (mean 5,277 IU/week) + IV iron sucrose (mean 185 mg/month)</td>
<td>↓NYHA class (3.7±0.5 to 2.7±0.7, P &lt;0.05), ↑LVEF (28±5% to 35±8%, P &lt;0.001), Decrease in diuretic dose Decrease in hospitalizations</td>
</tr>
<tr>
<td>Silverberg² 2001</td>
<td>Single center Randomized No placebo Open-label</td>
<td>NYHA III/IV, LVEF &lt;40% Hb 10-11.5 g/dL</td>
<td>16 Usual care</td>
<td>8.2 ± 2.6 months</td>
<td>10.3</td>
<td>12.5</td>
<td>12.9</td>
<td>S/C epoetin alfa (4,000 IU 1-3 x week) IV iron sucrose (200 mg/2 x weeks)</td>
<td>↓NYHA class, ↑LVEF +5.5% Decrease in diuretic dose Decrease in hospitalizations</td>
</tr>
<tr>
<td>Mancini³ 2003</td>
<td>Single center Single-blind Randomized Placebo-controlled</td>
<td>NYHA II/IV, Hct &lt;35%,</td>
<td>9 Control 17 Erythropoietin</td>
<td>3.0 months</td>
<td>11.0 ± 0.6</td>
<td>Hct &gt;45%</td>
<td>14.3 ± 1.2</td>
<td>S/C epoetin alfa 15,000 to 30,000 IU/ week + oral iron 325 mg and folate 1 mg daily</td>
<td>↑Peak VO₂ 11 ± 0.8 to 12.7 ± 2.8 mL/kg/min (P &lt;0.05), ↑6MWD, Improvement in MLWHFQ</td>
</tr>
<tr>
<td>Palazzuoli⁴ 2006</td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>NYHA II/IV Hb 11g/dL</td>
<td>20 Control 20 Erythropoietin</td>
<td>3.0 months</td>
<td>10.4 ± 0.6</td>
<td>NA</td>
<td>12.4 ± 0.8</td>
<td>Erythropoietin beta and oral iron</td>
<td>↓NYHA class, ↑exercise capacity, ↑Peak VO₂, ↓BNP</td>
</tr>
<tr>
<td>Palazzuoli⁵ 2007</td>
<td>Single center Randomized Double-blind Placebo-controlled</td>
<td>NYHA III/IV, LVEF &lt;40% Hb 9.0-12.0 g/dL Serum Cr 1.5-3.0 mg/dL</td>
<td>25 Control 26 Erythropoietin beta</td>
<td>12 months</td>
<td>10.4 ± 0.6</td>
<td>NA</td>
<td>12.4 ± 0.8</td>
<td>Erythropoietin beta 6,000 IU S/C 2 x week + oral iron 300 mg for 1 year</td>
<td>↑LVEF, ↓LV volumes, mass, ↓PAP and BNP, No change in serum Cr.</td>
</tr>
<tr>
<td>Ponikowski⁶ 2007</td>
<td>Multi-center Randomized Double-blind Placebo-controlled</td>
<td>Hb 9.0-12.0 g/dL, Peak VO₂ &lt;16 ml/kg/min</td>
<td>22 Placebo, 19 Darbepoetin</td>
<td>27 weeks</td>
<td>11.8 ± 0.2</td>
<td>13.0-15.0</td>
<td>13.9±0.4</td>
<td>Darbepoetin 0.75 µg/kg Q2W + 200-300 mg oral iron if serum ferritin &lt;800 µg/mL</td>
<td>Mean change in Peak VO₂ (45 ml/min, P=0.27), or (0.5 ml/kg/min, P = 0.40) Ex duration 108 sec (P=0.08), ↑PGA (79% vs. 41%, P = 0.01) No change in KCCQ/ MLHFQ No change in BNP or Cr</td>
</tr>
<tr>
<td>Author</td>
<td>Study Design</td>
<td>Inclusion Criteria</td>
<td>Patient (n)</td>
<td>Follow-up Duration</td>
<td>Baseline Hb (g/dL)</td>
<td>Target Hb (g/dL)</td>
<td>Achieved Hb (g/dL)</td>
<td>Agents and dose used</td>
<td>Outcomes</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>-------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>van Veldhuisen&lt;sup&gt;8&lt;/sup&gt; 2007</td>
<td>Multi-center Randomized Double-blind Placebo-controlled</td>
<td>Hb &gt;9.0 and &lt;12.5 g/dL, NYHA class II/III; CHF, LVEF &lt;40%</td>
<td>55 Placebo, 56 Darbepoetin (Wt. based), and 54 Darbepoetin (Fixed dose)</td>
<td>27 weeks</td>
<td>11.5</td>
<td>14 ± 1.0</td>
<td>13.3</td>
<td>Darbepoetin weight adjusted 0.75 µg/kg vs fixed dose 50 µg vs placebo Q2W + oral iron (200 mg daily if serum ferritin &lt;800 µg/L)</td>
<td>Rate of rise Hb 1.87 vs 1.64 g/dL in weight-based vs fixed dose (P=0.07), Improvement in KCCQ (P&lt;0.03), no significant improvement in 6MWD (P=0.074), PGA (P = 0.057), NYHA class, LVEF or MLWHFQ score</td>
</tr>
<tr>
<td>Parissis&lt;sup&gt;9&lt;/sup&gt; 2008</td>
<td>Randomized single-blind Placebo-controlled</td>
<td>Hb &lt;12.5 g/dL NYHA class II/III LVEF &lt;40% Cr &lt;2.5 mg/dL</td>
<td>11 Placebo, 21 Darbepoetin</td>
<td>12 weeks</td>
<td>Placebo 11.4, Darbepoetin 11.0</td>
<td>NA</td>
<td>Placebo 11.8, Darbepoetin 12.8</td>
<td>Darbepoetin weight adjusted 1.5 µg/kg every 20 days + oral iron vs placebo + oral iron</td>
<td>↓NYHA class, (P = 0.001) vs placebo ↑6 MWD (P &lt;0.001) vs placebo ↑ LVEF (P &lt;0.001) vs placebo</td>
</tr>
<tr>
<td>Kourea&lt;sup&gt;10&lt;/sup&gt; 2008</td>
<td>Randomized single-blind Placebo-controlled</td>
<td>Hb &lt;12.5 g/dL NYHA class II/III LVEF &lt;40% Cr &lt;2.5 mg/dL</td>
<td>20 Placebo, 21 Darbepoetin</td>
<td>12 weeks</td>
<td>Placebo 11.4, Darbepoetin 10.9</td>
<td>NA</td>
<td>Placebo 11.7, Darbepoetin 12.8</td>
<td>Darbepoetin weight adjusted 1.5 µg/kg every 20 days + oral iron vs placebo + oral iron</td>
<td>↑6 MWD (P &lt;0.001) vs placebo ↑ LVEF (P &lt;0.003) vs placebo ↑ KCCQ (P &lt;0.04) vs placebo</td>
</tr>
<tr>
<td>Ghali 2008&lt;sup&gt;11&lt;/sup&gt; STAMINA-HeFT</td>
<td>Multi-center Randomized Double-blind Placebo-controlled</td>
<td>Hb &gt;9.0 and &lt;12.5 g/dL, NYHA class II/IV; CHF, LVEF &lt;40%,</td>
<td>157 Placebo, 162 Darbepoetin</td>
<td>27 weeks for efficacy, 55 weeks for safety</td>
<td>11.4</td>
<td>14 ± 1.0</td>
<td>13.4 at 27 weeks, 13.4 at 53 weeks</td>
<td>Darbepoetin dose 0.75 µg/kg Q2W vs placebo + oral iron (200 mg daily if serum ferritin &lt;800 µg/L)</td>
<td>No significant difference in exercise duration, NYHA class or QoL scores at 27 weeks but trend to a decrease in the combined endpoint of death and hospitalization for HF</td>
</tr>
<tr>
<td>Abraham&lt;sup&gt;12&lt;/sup&gt; 2010*</td>
<td>Combined safety analysis of van Veldhuisen&lt;sup&gt;8&lt;/sup&gt; and Ghali 2008&lt;sup&gt;11&lt;/sup&gt;</td>
<td>Hb &gt;9.0 and &lt;12.5 g/dL, NYHA class II/III; CHF, LVEF &lt;40%</td>
<td>209 Placebo, 206 Darbepoetin</td>
<td>55 weeks</td>
<td>11.4 ± 0.8</td>
<td>14 ± 1.0</td>
<td>13.4</td>
<td>Darbepoetin dose 0.75 µg/kg or 50 µg vs placebo Q2W + oral iron (200 mg daily if serum ferritin &lt;800 µg/L)</td>
<td>Trend to a decrease in the combined endpoint of death and hospitalization for HF for darbepoetin vs placebo (HR, 0.67; 95% CI, 0.44, 1.03; P = 0.06)</td>
</tr>
</tbody>
</table>
## Supplemental Table 1 (continued)

<table>
<thead>
<tr>
<th>Author</th>
<th>Study Design</th>
<th>Inclusion Criteria</th>
<th>Patient (n)</th>
<th>Follow-up Duration</th>
<th>Baseline Hb (g/dL)</th>
<th>Target Hb (g/dL)</th>
<th>Achieved Hb (g/dL)</th>
<th>Agents and dose used</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cosyns&lt;sup&gt;13&lt;/sup&gt; 2010</td>
<td>Randomized Controlled</td>
<td>Hb &lt;12 g/dL, CHF, LVEF &lt;45%, CrCl &lt;45 mL/min</td>
<td>14 Placebo, 14 Erythropoietin</td>
<td>2 months</td>
<td>NA</td>
<td>NA</td>
<td>Control 10.1, erythropoietin 13.1</td>
<td>Erythropoietin vs control, dose NA</td>
<td>↓NYHA class, (P &lt;0.01) vs control, ↓ LV end-systolic and end-diastolic volumes, mitral regurgitation. ↑ LVEF and LV dP/dt (P &lt;0.001) vs control</td>
</tr>
<tr>
<td>Swedberg&lt;sup&gt;14&lt;/sup&gt; 2013 RED-HF</td>
<td>Multi-center Randomized Double-blind Placebo-controlled</td>
<td>Hb &gt;9.0 and &lt;12.0 g/dL, NYHA class II/III; CHF, LVEF &lt;40%</td>
<td>1142 Placebo, 1136 Darbepoetin</td>
<td>28 months</td>
<td>11.2 (10.6-11.6)</td>
<td>13.0 Not exceeding 14.5</td>
<td>13.0 (12.4-13.4)</td>
<td>Darbepoetin dose 0.75 µg/kg vs placebo Q2W until Hb 13g/dL and then to maintain Hb at 13 g/dL but exceeding 14.5 g/dL + oral iron (200 mg daily if serum ferritin &lt;800 µg/L</td>
<td>No effect on primary outcome of all-cause deaths or hospitalization for HF (HR 1.01; 95% CI, 0.90 to 1.13; P = 0.87). No effect on fatal or non-fatal MI, fatal or non-fatal strokes but 35% excess thrombotic events (P = 0.01)</td>
</tr>
</tbody>
</table>

* Combined safety results on studies described by Veldhuisen (2007)<sup>8</sup> and Ghali 2008<sup>11</sup>

6MWD, 6-minute walk distance; BNP, brain natriuretic peptide; Cr, creatinine; EPO, erythropoietin; Hb, hemoglobin; Hct, hematocrit; HF, heart failure; HR, Hazard ratio

IU, international units; IV, intravenous; KCCQ, Kansas City Cardiomyopathy Questionnaire; LV, left ventricular; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NYHA, New York Heart Association; PAP, systolic pulmonary artery pressure; PGA, Patient’s Global Assessment; Q2W, every 2 weeks

QoL, Quality of life; S/C, subcutaneous; VO<sub>2</sub> peak oxygen consumption; Wt., weight.
### Supplemental Table 2: Summary of Studies that Tested the Effects of Intravenous Iron in Patients with Anemia and Heart Failure.

<table>
<thead>
<tr>
<th>Author</th>
<th>Study Design</th>
<th>Inclusion Criteria</th>
<th>Patient (n)</th>
<th>Follow-up Duration</th>
<th>Baseline Hb (g/dL)</th>
<th>Achieved Hb (g/dL)</th>
<th>Agents and dose used</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolger15, 2006</td>
<td>Prospective uncontrolled</td>
<td>NYHA class II – III Mean LVEF 26%, Hb ≤12 g/dL</td>
<td>17</td>
<td>92 ± 6 days</td>
<td>11.2 ± 0.7</td>
<td>12.6 ± 1.2</td>
<td>1 g iron sucrose IV bolus x 12 days</td>
<td>↓ MLIHQ scores (33±19 to 19±14 (P=0.02)</td>
</tr>
<tr>
<td>Usmanov16, 2008</td>
<td>Prospective uncontrolled</td>
<td>NYHA class III and IV Hb &lt;11 g/dL CKD</td>
<td>32</td>
<td>26 weeks</td>
<td>NYHA IV 9.4 ± 0.6</td>
<td>NYHA IV 12 ± 0.8</td>
<td>100 mg iron sucrose IV three times/week for 26 weeks</td>
<td>↓ in NYHA class III No change in NYHA class IV ↑ in Hb Improvement in LV remodeling</td>
</tr>
<tr>
<td>Tobli17, 2007</td>
<td>Randomized Double-blind Placebo-controlled</td>
<td>Hb &lt;12.5 g/dL, TSAT &lt;20%, Ferritin &lt;100 µg/L, CrCl &lt;90 ml/min, LVEF ≤35%</td>
<td>20 Saline</td>
<td>6 months</td>
<td>Placebo 10.2 ± 0.5</td>
<td>IV iron sucrose 10.3 ± 0.6</td>
<td>200 mg iron sucrose weekly for 5 weeks</td>
<td>↑ in Hb 1.4 g/dL ↑ LVEF 36 ± 4.7 vs. 29 ± 2.4 (P &lt;0.01) ↓ NT-proBNP 118±87 vs. 451±249 pg/mL, P &lt;0.01 ↓ CRP (2.3±0.8 vs. 6.5±3.7 mg/L, P &lt;0.01) ↑ 6MWD (P &lt;0.01) ↑ MLHFFQ scores (P &lt;0.01)</td>
</tr>
<tr>
<td>Okonko2008, FAIR-HF</td>
<td>Randomized Observer-blinded Placebo-controlled</td>
<td>NYHA class II-III, anemic (Hb &lt;12.5 g/dL) or non-anemic (Hb &gt;12.5 g/dL) Ferritin &lt;100 µg/L or ferritin 100-300 µg/L with TSAT &lt;20% Peak VO2 &lt;18 ml/kg/min</td>
<td>11 Control</td>
<td>18 weeks</td>
<td>Placebo 12.2 ± 1.0</td>
<td>IV iron sucrose 12.6 ± 1.2</td>
<td>200 mg weekly until ferritin &gt;500 µg/L, 200 mg monthly thereafter</td>
<td>↑ in Peak VO2 (P = 0.009) ↓ in NYHA class (P =0.007)</td>
</tr>
<tr>
<td>Anker2009, FAIR-HF</td>
<td>Randomized Double-blind Placebo-controlled</td>
<td>NYHA class II, LVEF &lt;40% NYHA class III, LVEF &lt;45% Hb 9.5-13.5 g/dL Ferritin &lt;100 µg/L or ferritin 100-300 µg/L with TSAT&lt;20%</td>
<td>155 Placebo</td>
<td>24 weeks</td>
<td>Placebo 11.9 ± 1.4</td>
<td>Placebo 12.5 ± 1.0</td>
<td>200 mg weekly until ferritin &gt;500 µg/L, 200 mg monthly thereafter</td>
<td>PGA improved (P &lt;0.001) ↑ KCCQ QoL (P &lt;0.001) ↑ EQ-5D Score ↑ 6MWD</td>
</tr>
<tr>
<td>Beck-da-Silva2013, IRON-HF</td>
<td>Randomized Double-blind Placebo-controlled</td>
<td>NYHA class II, LVEF &lt;40% Anemia (Hb 9.0-12.0 g/dL) Ferritin &lt;500 µg/L and TSAT &lt;20%</td>
<td>6 Placebo 10 IV iron sucrose</td>
<td>5 weeks to 3 months</td>
<td>Placebo 10.9 ± 0.7</td>
<td>Placebo 10.7 ± 0.2</td>
<td>Iron sucrose 200 mg/week x 5; Oral ferrous sulfate 200 mg tid for 8 weeks versus placebo</td>
<td>↑ Peak VO2 by 3.5 ml/kg/min in IV group ↓ Peak VO2 by 0.86 in oral iron ↑ Peak VO2 by 1.86 in placebo</td>
</tr>
</tbody>
</table>

**Notes:**
- Baseline Hb: Hemoglobin at the start of the study.
- Achieved Hb: Hemoglobin at the end of the study.
- Agents and dose used: Dosage and method of administration.
- Outcomes: Changes in biomarkers and functional outcomes related to the study’s primary endpoint.
## Supplemental Table 2 (continued)

<table>
<thead>
<tr>
<th>Author</th>
<th>Study Design</th>
<th>Inclusion Criteria</th>
<th>Patient (n)</th>
<th>Follow-up Duration</th>
<th>Baseline Hb (g/dL)</th>
<th>Achieved Hb (g/dL)</th>
<th>Agents and dose used</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ponikowski 2015&lt;sup&gt;31&lt;/sup&gt; CONFIRM-HF</td>
<td>Randomized Double-blind Placebo-controlled</td>
<td>NYHA class II, LVEF &lt;45%, BNP &gt;100 pg/mL, NT-proBNP &gt;400 pg/mL, Hb &lt;15 g/dL, Ferritin &lt;100 µg/L or 100-300 µg/L if TSAT &lt;20%</td>
<td>152 Saline 152 FCM</td>
<td>52 weeks</td>
<td>Placebo 12.4 ± 1.3</td>
<td>FCM 12.37 ± 1.4</td>
<td>FCM 500-2000 mg at baseline and week 6 then 500 mg at weeks 12, 24, &amp; 36 if ID still present</td>
<td>PGA improved (P &lt;0.001)</td>
</tr>
<tr>
<td>van Veldhuisen 2017&lt;sup&gt;22&lt;/sup&gt; EFFECT-HF</td>
<td>Randomized controlled</td>
<td>NYHA class II-III, LVEF &lt;45%, BNP &gt;100 pg/mL, NT-proBNP &gt;400 pg/mL, Hb &lt;15 g/dL, Ferritin &lt;100 µg/L or 100-300 µg/L if TSAT &lt;20%, Peak VO&lt;sub&gt;2&lt;/sub&gt; 10 to 20 ml/kg/min</td>
<td>86 Control 86 FCM</td>
<td>24 weeks</td>
<td>Control 13 ± 1.5</td>
<td>FCM 12.9 ± 1.3</td>
<td>FCM 500-1000 mg at baseline and week 6 based on weight and Hb then at week 12 if ID still present</td>
<td>△ Peak VO&lt;sub&gt;2&lt;/sub&gt; by -0.16 ml/kg/min in FCM and -0.63 ml/kg/min in control (P = 0.23) not imputed</td>
</tr>
</tbody>
</table>

6MWD, 6-minute walk distance; CrCl, creatinine clearance; CRP, C-reactive protein; Hb, hemoglobin; IV, intravenous; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NT-proBNP, N-terminal brain natriuretic peptide; NYHA, New York Heart Association;

PGA, Patient’s Global Assessment; TSAT, Transferrin saturation; VO<sub>2</sub>, peak oxygen consumption.
### Supplemental Table 3: Recently Completed and Ongoing Trials of Intravenous Iron Supplementation in Patients with Heart Failure (Registered with ClinicalTrials.gov)

<table>
<thead>
<tr>
<th>Trial name, ClinicalTrials.gov ID</th>
<th>Status</th>
<th>Study Design</th>
<th>Inclusion Criteria</th>
<th>Number of subjects</th>
<th>Study duration</th>
<th>Intravenous iron preparation used</th>
<th>Primary Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pilot RAndomized Controlled Trial of FerrIC Carboxymaltose in ASIAns With Heart Failure. PRACTICE-ASIA-HF, NCT01922479</td>
<td>Completed</td>
<td>Randomized, placebo-controlled, phase 4</td>
<td>Acutely decompensated HF (regardless of LVEF), TSAT &lt;20%, ferritin &lt;300 µg/L and Hb ≤14 g/dL</td>
<td>50</td>
<td>12 weeks</td>
<td>FCM (1,000 mg) vs placebo</td>
<td>Change in 6MWD from baseline to 4th and 12th week.</td>
</tr>
<tr>
<td>Short-Term Effects &amp; Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure, NCT01925703</td>
<td>Completed</td>
<td>Single arm, phase 4</td>
<td>Admitted with HF, NYHA II-IV, LVEF &lt;40%, Hb &lt;12.0 g/dL, ferritin &lt;100 µg/L or 100-299 µg/L with TSAT &lt;20%.</td>
<td>13</td>
<td>4 weeks</td>
<td>Sodium ferric gluconate 250 mg every 12 hours until iron repletion completed (as determined by Ganzoni formula) or patient discharge, whichever comes first.</td>
<td>Change in Hb compared to baseline and at follow-up within 1-4 weeks after last iron infusion</td>
</tr>
<tr>
<td>Iron in Congestive Heart Failure (iCHF) Randomized, Double-blind, Placebo-controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients With Congestive Heart Failure. NCT01837082</td>
<td>Terminated</td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>LVEF ≤45%, NYHA II-III, iron deficiency</td>
<td>18 subjects enrolled</td>
<td>12 weeks</td>
<td>FCM vs placebo</td>
<td>Change in LVEF by cardiac MRI from baseline to 12 weeks</td>
</tr>
<tr>
<td>Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease, NCT00384657</td>
<td>Withdrawn</td>
<td>Randomized, open label, phase 3</td>
<td>LVEF &lt;40%, NYHA III, stable stage 3 chronic kidney disease (eGFR 30-59 mL/min/1.73 m²), Hb &lt;12 g/dL, ferritin &lt;100 µg/L or ferritin 100-299 µg/L and TSAT &lt;20%</td>
<td>200 (no subjects enrolled)</td>
<td>12 months</td>
<td>Treatment: Ferric sucrose 200 mg weekly ≤ 4, then every other week until Hb ≥ 12 g/dL, then 100 mg every 2-4 weeks to maintain Hb and ferritin ≤ 500 µg/L. Iron held for ferritin &gt; 500 µg/L. Control: Conventional HF treatment.</td>
<td>Percentage of patients with increased LVEF at 12 months</td>
</tr>
</tbody>
</table>
## Supplemental Table 3 (continued)

<table>
<thead>
<tr>
<th>Trial name, ClinicalTrials.gov ID</th>
<th>Status</th>
<th>Study Design</th>
<th>Inclusion Criteria</th>
<th>Number of subjects</th>
<th>Study duration</th>
<th>Intravenous iron preparation used</th>
<th>Primary Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Randomized, Double-Blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalizations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure. AFFIRM-AHF, NCT02937454</td>
<td>Recruiting</td>
<td>Randomized, double-blind, placebo controlled, phase 4</td>
<td>Acute HF randomized before discharge from hospital, ferritin &lt;100 µg/L or ferritin 100-299 µg/L with TSAT &lt;20%, prior LVEF &lt;50%</td>
<td>1,100</td>
<td>12 months</td>
<td>FCM (first dose prior to discharge, subsequent doses as outpatient, based on weight and Hb) vs placebo</td>
<td>HF hospitalizations and CV death (composite endpoint)</td>
</tr>
<tr>
<td>Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity &amp; Mortality. FAIR-HF2, NCT03036462</td>
<td>Recruiting</td>
<td>Randomized, double-blind, placebo controlled, phase 4</td>
<td>HF, confirmed iron deficiency, Hb 9.5-14.0 g/dL</td>
<td>1,200</td>
<td>12 months</td>
<td>FCM (1,000 mg, then 500-1,000 mg within 4 weeks [max 2,000 mg total], then 500 mg every 4 months except with Hb &gt;16 g/dL or ferritin &gt;800 µg/L) vs placebo</td>
<td>HF hospitalizations and CV death (composite endpoint)</td>
</tr>
<tr>
<td>A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency. HEART-FID, NCT03037931</td>
<td>Recruiting</td>
<td>Randomized, double-blind, placebo controlled, phase 3</td>
<td>NYHA II-IV, LVEF ≤35% or LVEF ≤25% in prior 2 years, Hb &gt;9.0 g/dL and &lt;13.5 g/dL (F) or &lt;15.0 g/dL (M), ferritin &lt;100 µg/L or 100-299 µg/L with TSAT &lt;20%, either hospitalization for HF within 12 months or elevated natriuretic peptides.</td>
<td>3,014</td>
<td>12 months</td>
<td>FCM (2 doses of 15 mg/kg to a maximum individual dose of 750 mg 7 days apart and a maximum combined dose of 1,500 mg, repeated every 6 months as indicated by iron indices) vs placebo</td>
<td>Rates of death and hospitalization for worsening heart failure at 1 year, and change in 6MWD at 6 months</td>
</tr>
<tr>
<td>Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomized, Open-label Multicenter Trial. IRONMAN, NCT02642562</td>
<td>Recruiting</td>
<td>Randomized, single blind, phase 4</td>
<td>NYHA II-IV, LVEF &lt;45%, Hb ≥9.0 g/dL and ≤13.0 g/dL (F) or ≤14.0 g/dL (M), ferritin &lt;100 µg/L and/or TSAT &lt;20% (with ferritin ≤400 µg/L), either hospitalization for HF within 6 months or elevated natriuretic peptides.</td>
<td>1,299</td>
<td>At least 30 months</td>
<td>Iron isomaltoside (doses based on weight and Hb) vs &quot;usual care&quot;</td>
<td>CV mortality or hospitalization for worsening HF</td>
</tr>
</tbody>
</table>
### Supplemental Table 3 (continued)

<table>
<thead>
<tr>
<th>Trial name, ClinicalTrials.gov ID</th>
<th>Status</th>
<th>Study Design</th>
<th>Inclusion Criteria</th>
<th>Number of subjects</th>
<th>Study duration</th>
<th>Intravenous iron preparation used</th>
<th>Primary Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency, NCT03042130</td>
<td>Not yet recruiting</td>
<td>Randomized, open label, phase 4</td>
<td>NYHA III-IV, LVEF &lt;40%, Hb &gt;10 g/dL, serum iron &gt; 50 µg/dL, TSAT &gt;20%</td>
<td>60</td>
<td>1 month</td>
<td>FCM (2 doses) vs &quot;standard of care&quot;</td>
<td>Improvements in NYHA class and QoL (KCCQ score)</td>
</tr>
<tr>
<td>Effect of IV Iron (Ferric Carboxymaltose, Ferinject) on Exercise Tolerance, Symptoms and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and Iron Deficiency With and Without Anemia. FAIR-HFpEF, NCT03074591</td>
<td>Recruiting</td>
<td>Randomized phase 2</td>
<td>HF with preserved LVEF (HFpEF) and diastolic dysfunction, LVEF ≥45%, NYHA II-III, either HF hospitalization within 1 year or elevated natriuretic peptides, Hb &gt;9.0 g/dL and ≤14.0 g/dL, ferritin &lt;100 µg/L or ferritin 100-299 with TSAT &lt;20%, 6MWD &lt;450 m</td>
<td>200</td>
<td>12 months</td>
<td>FCM vs placebo</td>
<td>Exercise capacity: change in 6MWD from baseline to 12 months</td>
</tr>
<tr>
<td>Changes in myocardial iron after iron administration. MYOCARDIAL IRON, NCT03398681</td>
<td>Recruiting</td>
<td>Randomized, triple-blind, placebo controlled, phase 4</td>
<td>NYHA II-III, LVEF &lt;50%, Hb &lt;15.0 g/dL, ferritin &lt;100 µg/L or 100 - 299 µg/L with TSAT &lt;20%, elevated natriuretic peptides.</td>
<td>50</td>
<td>30 days</td>
<td>FCM (1000 mg) vs placebo</td>
<td>Change in myocardial iron content at 7 and 30 days, assessed by cardiac T2* and T1-mapping MRI</td>
</tr>
<tr>
<td>Differential Gene Expression in Patients With HF and Iron Deficiency - Effects of FCM. NCT01978028</td>
<td>Recruiting</td>
<td>Randomized, triple-blind, placebo controlled, phase 4</td>
<td>LVEF ≤40% (NYHA II) or LVEF ≤45% (NYHA III), Hb 9.5-13.5 g/dL, ferritin &lt;100 µg/L or 100 - 299 µg/L with TSAT &lt;20%,</td>
<td>20</td>
<td>12 weeks</td>
<td>FCM vs placebo</td>
<td>Change in mitochondrial gene activation pattern at 12 weeks</td>
</tr>
<tr>
<td>FCM to Improve Skeletal Muscle Metabolism in HF Patients With Functional Iron Deficiency. NCT03218384</td>
<td>Recruiting</td>
<td>Randomized, double-blind, placebo controlled, phase 2</td>
<td>NYHA II-III, LVEF &lt;40% or LVEF ≥40% with left atrial enlargement or LV hypertrophy, Hb &gt;13 g/dL (M) and &gt;12 g/dL (F)</td>
<td>32</td>
<td>4 weeks</td>
<td>FCM (750 mg) vs placebo</td>
<td>Change in skeletal muscle mitochondrial oxidative capacity at 4 weeks: post-exercise phosphocreatine recovery time measured non-invasively with 31P-magnetic resonance spectroscopy.</td>
</tr>
</tbody>
</table>

6MWD, 6-minute walk distance; F, females; FCM, ferric carboxymaltose; HF, heart failure; LVEF, left ventricular ejection fraction; M, males; MRI, magnetic resonance imaging; TSAT, transferrin saturation.
A meta-analysis of 11 small phase 2 randomized controlled studies comprising 657 patients showed that treatment of anemia with ESA improved (A) hemoglobin level, (B) left ventricular ejection fraction, (C) exercise capacity and (D) NYHA class. Weighted mean differences are shown on a logarithmic scale; the size of each square is proportional to the weight of the individual study, and the diamond represents the pooled difference using a random effects model. $I^2$ is the percentage of total variation across studies due to heterogeneity.

Figure reproduced from Kotecha D et al. Am Heart J 2011;161:822-831 e822\(^3\) with permission from Elsevier.
Supplemental Figure 2: Effect of ESA Therapy on Hospitalizations for Heart Failure and All-Cause Mortality from the Meta-analysis of Phase 2 Randomized Controlled Studies.

A: Heart Failure Hospitalizations

<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment Events</th>
<th>Control Events</th>
<th>Weight</th>
<th>Peto Odds Ratio [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cleland 2005</td>
<td>3 15</td>
<td>0 6</td>
<td>2.2%</td>
<td>4.51 [0.28, 86.37]</td>
</tr>
<tr>
<td>Ghiati 2008</td>
<td>25 162</td>
<td>31 157</td>
<td>50.6%</td>
<td>0.74 [0.42, 1.32]</td>
</tr>
<tr>
<td>Kurea 2008</td>
<td>3 21</td>
<td>5 20</td>
<td>7.2%</td>
<td>0.51 [0.11, 2.36]</td>
</tr>
<tr>
<td>Mancini 2003</td>
<td>1 15</td>
<td>4 8</td>
<td>4.1%</td>
<td>0.09 [0.01, 0.67]</td>
</tr>
<tr>
<td>Palazzuoli 2006</td>
<td>4 20</td>
<td>8 18</td>
<td>9.2%</td>
<td>0.33 [0.09, 1.28]</td>
</tr>
<tr>
<td>Palazzuoli 2007</td>
<td>4 26</td>
<td>8 25</td>
<td>10.2%</td>
<td>0.40 [0.11, 1.46]</td>
</tr>
<tr>
<td>Parisis 2006</td>
<td>2 21</td>
<td>3 11</td>
<td>4.3%</td>
<td>0.27 [0.04, 1.96]</td>
</tr>
<tr>
<td>Ponikowski 2007</td>
<td>2 19</td>
<td>3 22</td>
<td>4.9%</td>
<td>0.75 [0.12, 4.86]</td>
</tr>
<tr>
<td>van Veldhuisen 2007</td>
<td>4 110</td>
<td>4 55</td>
<td>7.4%</td>
<td>0.46 [0.10, 2.05]</td>
</tr>
</tbody>
</table>

Total: ESA (48/412) versus control (66/322) 0.56 [0.37, 0.84]

B: All-Cause Mortality

<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment Events</th>
<th>Control Events</th>
<th>Weight</th>
<th>Peto Odds Ratio [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cleland 2005</td>
<td>1 18</td>
<td>1 6</td>
<td>2.7%</td>
<td>0.25 [0.01, 6.54]</td>
</tr>
<tr>
<td>Ghiati 2008</td>
<td>11 162</td>
<td>18 157</td>
<td>49.0%</td>
<td>0.57 [0.27, 1.22]</td>
</tr>
<tr>
<td>Kurea 2008</td>
<td>1 21</td>
<td>3 20</td>
<td>6.9%</td>
<td>0.32 [0.04, 2.47]</td>
</tr>
<tr>
<td>Mancini 2003</td>
<td>1 15</td>
<td>0 8</td>
<td>1.7%</td>
<td>4.63 [0.08, 283.88]</td>
</tr>
<tr>
<td>Palazzuoli 2006</td>
<td>1 20</td>
<td>2 18</td>
<td>5.2%</td>
<td>0.44 [0.04, 4.54]</td>
</tr>
<tr>
<td>Palazzuoli 2007</td>
<td>3 26</td>
<td>4 25</td>
<td>11.4%</td>
<td>0.69 [0.14, 3.35]</td>
</tr>
<tr>
<td>Parisis 2006</td>
<td>0 21</td>
<td>2 11</td>
<td>3.2%</td>
<td>0.05 [0.00, 0.96]</td>
</tr>
<tr>
<td>Ponikowski 2007</td>
<td>1 19</td>
<td>1 22</td>
<td>3.6%</td>
<td>1.16 [0.07, 19.41]</td>
</tr>
<tr>
<td>Silverberg 2001</td>
<td>0 16</td>
<td>4 16</td>
<td>6.7%</td>
<td>0.11 [0.01, 0.86]</td>
</tr>
<tr>
<td>van Veldhuisen 2007</td>
<td>6 108</td>
<td>0 55</td>
<td>9.6%</td>
<td>4.75 [0.85, 26.48]</td>
</tr>
</tbody>
</table>

Total: ESA (25/426) versus control (35/333) 0.58 [0.34, 0.99]

Effect of ESA therapy on clinical outcomes including (A) heart failure hospitalizations and (B) all-cause mortality, from the meta-analysis of 11 small phase 2 randomized controlled studies. Odds ratios are shown on a logarithmic scale; the size of each square is proportional to the weight of the individual study, and the diamond represents the pooled difference using a fixed effects model.

Figure reproduced from Kotecha D et al. Am Heart J 2011;161:822-831 e822\(^1\) with permission from Elsevier.
References for Supplemental Materials


